Global Information
회사소개 | 문의 | 비교리스트

폐경기후 골다공증 : 파이프라인 리뷰

Post Menopausal Osteoporosis - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 213136
페이지 정보 영문 129 Pages
가격
US $ 2,000 ₩ 2,402,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,804,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,206,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


폐경기후 골다공증 : 파이프라인 리뷰 Post Menopausal Osteoporosis - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 129 Pages

폐경기후 골다공증이란 골다공증의 가장 일반적인 형태로, 폐경기후 여성의 대부분이 걸립니다. 등의 통증 및 신장 감소, 전굴 자세 등의 척추 변형 증상이 있습니다. 연령, 성별, 가족력, 뼈구조, 체중 등의 위험인자가 있으며, 호르몬 대체 요법(HRT), 비타민 D3 유사체 투여 등의 치료법이 있습니다.

세계의 폐경기후 골다공증(Post Menopausal Osteoporosis) 치료제 파이프라인에 대해 조사분석했으며, 현재 개발 파이프라인의 상황 및 최신 동향, 약제 개요, 주요 기업 및 개발중인 제품 리뷰 등을 정리하여 전해드립니다.

서론

  • 조사 범위

폐경기후 골다공증 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 치료제
  • 기업에서 개발중인 제품

폐경기후 골다공증 : 치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

폐경기후 골다공증 치료제 개발 참여 기업

  • Amgen Inc
  • Enteris BioPharma Inc
  • Intas Pharmaceuticals Ltd
  • Ipsen SA
  • Ligand Pharmaceuticals Inc
  • Lupin Ltd
  • NIBEC
  • Oncobiologics Inc
  • Paras Biopharmaceuticals Finland Oy

약제 프로파일

폐경기후 골다공증 : 휴지 상태인 프로젝트

폐경기후 골다공증 : 개발이 중지된 제품

폐경기후 골다공증 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 17.06.05

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Post Menopausal Osteoporosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Ablynx NV, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by AlphaMab Co Ltd, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Amgen Inc, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Aryogen Pharmed Co, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Entera Bio Ltd, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Enteris BioPharma Inc, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Enzene Biosciences Ltd, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Epygen Biotech Pvt Ltd, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Genor BioPharma Co Ltd, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Hengenix Biotech Inc, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Hualan Biological Engineering Inc, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by InSight Biopharmaceuticals Ltd, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Ipsen SA, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by JHL Biotech Inc, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Jiangsu T-mab BioPharma Co Ltd, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Lupin Ltd, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Luye Pharma Group Ltd, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Metabolab Inc, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Nano Intelligent Biomedical Engineering Corp, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Nanomedic Inc, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by NeuClone Pty Ltd, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Qilu Pharmaceutical Co Ltd, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Sandoz International GmbH, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Shandong Danhong Pharmaceutical Co Ltd, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Shanghai Biomabs Pharmaceuticals Co Ltd, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by Uni-Bio Science Group Ltd, H1 2020
  • Post Menopausal Osteoporosis - Pipeline by USV Pvt Ltd, H1 2020
  • Post Menopausal Osteoporosis - Dormant Projects, H1 2020
  • Post Menopausal Osteoporosis - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Post Menopausal Osteoporosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H1 2020, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.

Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 1, 8, 1, 8, 3 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Post Menopausal Osteoporosis - Overview
  • Post Menopausal Osteoporosis - Therapeutics Development
  • Post Menopausal Osteoporosis - Therapeutics Assessment
  • Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development
  • Post Menopausal Osteoporosis - Drug Profiles
  • Post Menopausal Osteoporosis - Dormant Projects
  • Post Menopausal Osteoporosis - Discontinued Products
  • Post Menopausal Osteoporosis - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q